Cargando…

Targeted Therapies and Biomarkers in Small Cell Lung Cancer

Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid growth, early metastasis, and acquired therapeutic resistance. A majority of patients with SCLC have extensive-stage (ES) disease, defined as the presence of metastatic disease outside the hemithorax at first diagnosis....

Descripción completa

Detalles Bibliográficos
Autores principales:	Taniguchi, Hirokazu, Sen, Triparna, Rudin, Charles M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251180/ https://www.ncbi.nlm.nih.gov/pubmed/32509576 http://dx.doi.org/10.3389/fonc.2020.00741

Ejemplares similares

CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future
por: Uddin, Fathema, et al.
Publicado: (2020)

Targeted therapy of RET fusion-positive non-small cell lung cancer
por: Shen, Zixiong, et al.
Publicado: (2022)

NFAT as a Biomarker and Therapeutic Target in Non–Small Cell Lung Cancer–Related Brain Metastasis
por: Peng, Lu, et al.
Publicado: (2021)

Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer
por: Yang, Ping, et al.
Publicado: (2022)

The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases
por: Billena, Cole, et al.
Publicado: (2023)

Targeting KRAS in Non-Small Cell Lung Cancer
por: Corral de la Fuente, Elena, et al.
Publicado: (2022)

Maintenance Therapies for Non-Small Cell Lung Cancer
por: Blais, Normand, et al.
Publicado: (2014)

Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer
por: Ryan, Sarah-Louise, et al.
Publicado: (2021)

Small cell lung cancer transformation and tumor heterogeneity after sequential targeted therapy and immunotherapy in EGFR-mutant non-small cell lung cancer: A case report
por: Yang, Meng-Hang, et al.
Publicado: (2022)

The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer
por: Wong, Annick
Publicado: (2017)

Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
por: Tartarone, Alfredo, et al.
Publicado: (2021)

CDK7 is a prognostic biomarker for non-small cell lung cancer
por: Kuempers, Christiane, et al.
Publicado: (2022)

Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer
por: Hong, Yang, et al.
Publicado: (2021)

Radiation Therapy in Extensive Stage Small Cell Lung Cancer
por: Jeremic, Branislav, et al.
Publicado: (2017)

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
por: Lin, Chen, et al.
Publicado: (2020)

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer
por: Spaans, Johanna N., et al.
Publicado: (2014)

MET-targeted therapies for the treatment of non-small-cell lung cancer: A systematic review and meta-analysis
por: Xu, Linrui, et al.
Publicado: (2022)

Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
por: Yang, Jialiang, et al.
Publicado: (2021)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

The use of nanoparticles for targeted drug delivery in non-small cell lung cancer
por: Holder, Jessica E., et al.
Publicado: (2023)

Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer
por: Rybinski, Brad, et al.
Publicado: (2020)

Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy
por: Li, Qingsong, et al.
Publicado: (2023)

Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
por: Liu, Hao, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Small Academic Hospital Experience
por: Factor, Oren B., et al.
Publicado: (2014)

Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer
por: Peng, Muyun, et al.
Publicado: (2020)

Tumor-Derived Exosomal miRNAs as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
por: Zhang, Zhijun, et al.
Publicado: (2020)

Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
por: Yuan, Shuai, et al.
Publicado: (2020)

The Potential of Heavy-Ion Therapy to Improve Outcomes for Locally Advanced Non-Small Cell Lung Cancer
por: Chun, Stephen G., et al.
Publicado: (2017)

Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021)

CCKAR is a biomarker for prognosis and asynchronous brain metastasis of non-small cell lung cancer
por: Liang, Nan, et al.
Publicado: (2023)

MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer
por: Caeser, Rebecca, et al.
Publicado: (2021)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
por: Michaels, Elena, et al.
Publicado: (2022)

Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist’s Perspective
por: Brega, Elisa, et al.
Publicado: (2014)

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
por: Han, Yanjie, et al.
Publicado: (2023)

Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer
por: Yang, Yu-Chen, et al.
Publicado: (2023)

Local therapy treatment conditions for oligometastatic non-small cell lung cancer
por: Zhang, Suli, et al.
Publicado: (2022)

Editorial: Application of nanotechnology in diagnosis and/or therapy of non-small cell lung cancer
por: Shen, Qinglin, et al.
Publicado: (2023)

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity
por: van den Broek, Daan, et al.
Publicado: (2020)

WDR5 is a prognostic biomarker of brain metastasis from non-small cell lung cancer
por: Li, Zheng, et al.
Publicado: (2022)

Plasma exosomal tRNA‐derived fragments as diagnostic biomarkers in non-small cell lung cancer
por: Zheng, Baibing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7shi7c7m1qd137vhm426fkvsk1